目的 研究異甘草酸鎂對難治性腎病綜合征患者藥物所致肝損傷的臨床療效。方法 選擇2014年3月-2015年12月在內(nèi)蒙古林業(yè)總醫(yī)院進行診治的因治療藥物引起肝損傷的難治性腎病綜合征患者86例，按數(shù)字法隨機分為兩組，對照組給予復方甘草酸單胺，觀察組給予異甘草酸鎂，均治療2周。分別于治療前后檢測天門冬氨酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）、谷氨酰轉(zhuǎn)肽酶（y-GT）、總膽汁酸（TBA）等肝功能指標；并記錄患者臨床癥狀和體征的復常情況，臨床療效以及不良反應發(fā)生情況。結(jié)果 治療前兩組AST、ALT、y-GT、TBA比較，差異無顯著性；兩組治療后的AST、ALT、y-GT、TBA均明顯降低（P<0.05），且觀察組的降低程度明顯優(yōu)于對照組（P<0.05）；觀察組的臨床癥狀和體征改善情況明顯優(yōu)于對照組（P<0.05），且觀察組的臨床癥狀和體征復常時間明顯短于對照組（P<0.05）；觀察組有效率為95.35%，明顯高于對照組79.07%（P<0.05）；兩組不良反應發(fā)生率相比無明顯差異。結(jié)論 異甘草酸鎂能明顯改善難治性腎病綜合征患者藥物所致肝損傷，安全有效，具有較高的臨床應用價值。

Objective To investigate the clinical effect of magnesium isoglycyrrhizinate on liver injury induced by drugs in patients with refractory nephrotic syndrome. Methods Totally 86 cases of patients with refractory nephrotic syndrome in Inner Mongolia Forestry General Hospital from March 2014 to December 2015 were selected and divided into two groups randomly, 43 cases in each group. The patients in control group were treated with potenlin, and the patients in observation group were treated with magnesium isoglycyrrhizinate. All patients were treated for 2 weeks. The liver function indexes such as AST, ALT, y-GT, and TBA were detected before and after treatment. The recovery of clinical symptoms and signs of patients, clinical efficacy, and adverse reactions were recorded. Results Before treatment, there were no significant difference of AST, ALT, y-GT, and TBA between the two groups. After treatment, the AST, ALT, y-GT, and TBA in the two groups were significantly lower than before treatment (P<0.05), and the observation group reduce significantly superior to the control group (P<0.05). In the observation group, the improvement of clinical symptoms and signs was better than that of the control group (P<0.05) and recovery time of clinical symptoms and signs in the observation group was significantly shorter than that of the control group (P<0.05). The effective rate of the observation group was 95.35%, significantly higher than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Magnesium can significantly improve the liver injury induced by drugs in patients with refractory nephrotic syndrome, and it is safe and effective, with a high clinical value.